Introduction
============

Breast cancer is one of the most common types of cancer and the leading cause of cancer related death in women worldwide ([@B44]). More than 70% of affected patients are ER-positive and therefore eligible for adjuvant endocrine therapy with tamoxifen ([@B10]; [@B17]). This drug has been the gold standard treatment of ER-positive breast cancer patients for more than three decades ([@B20]). Tamoxifen acts as an estrogen antagonist and thus inhibits ER-dependent cell proliferation in breast cancer cells ([@B21]). Tamoxifen decreases the risk of recurrence and mortality by 50 and 30%, respectively. Even so, the efficacy of tamoxifen shows a high degree of variation, with 30--50% of patients exhibiting drug resistance ([@B10]).

Tamoxifen is extensively metabolized by several members of the cytochrome P450 enzymes ([@B8]; [@B5]). Some of the resulting metabolites have higher anti-estrogenic effects in breast cancer tissue than tamoxifen itself. Among these, 4-hydroxytamoxifen (4-OH-Tam) and 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) show the highest anti-estrogenic potency ([@B28]). As the steady state plasma concentration of endoxifen is approx. 10-times higher compared with levels of 4-OH-Tam, endoxifen is considered to be the major active tamoxifen metabolite ([@B42]).

The bioactivation of tamoxifen to its main active metabolite endoxifen comprises two permutable steps, namely N-desmethylation and 4-hydroxylation ([Figure 1](#F1){ref-type="fig"}; [@B5]). The rate limiting step in the major route is the 4-hydroxylation via CYP2D6 ([@B8]).

![Metabolism of tamoxifen. Structures, names, and abbreviations of all metabolites which were quantified in the present study are shown ([@B5]).](fphar-10-00530-g001){#F1}

CYP2D6 is encoded by a highly polymorphic gene with more than 100 different alleles ([@B40]). It has been shown that a number of its genetic variants affect the activity of the enzyme and may decrease the levels of the active metabolites and thus result in decreased therapeutic response to tamoxifen ([@B13]; [@B34]; [@B38]). According to the enzyme activity, four different phenotypic alleles including PM, IM, EM, and UM have been categorized ([@B4]; [@B6]; [@B47]; [@B45]; [@B31]). There is a body of evidence that subjects carrying dysfunctional alleles of *CYP2D6* have less benefit from tamoxifen therapy because of lower plasma concentrations of the active metabolite endoxifen ([@B19]; [@B26]; [@B29]; [@B22]; [@B37]).

The frequency of *CYP2D6* alleles varies in different populations. Various studies indicate that the prevalence of normal alleles (^∗^1 and ^∗^2) in the European population is around 70%. Twenty-six percent of the population in Europe is carrying one PM (^∗^3, ^∗^4, ^∗^5, and ^∗^6) allele and the most common PM allele is *CYP2D6*^∗^4. However, the frequency of PM alleles in the Asian population is less than 1%. In contrast, in the Asian population between the reduced function alleles (^∗^10, ^∗^17, and ^∗^41), *CYP2D6*^∗^10 is significantly more frequent by about 40--50% compared to Europeans ([@B4]).

Regarding the Iranian population and the ethnic background few studies indicate the most relevant *CYP2D6* alleles ([@B25]; [@B15]; [@B2]). Accordingly, we decided to genotype the breast cancer patients of our study for the *CYP2D6* alleles *^∗^1, ^∗^2, ^∗^4, ^∗^5, ^∗^6, ^∗^10, ^∗^17*, and *^∗^41* as well as the gene duplication to comprehensively cover *CYP2D6* alleles representative of the Iran population (Isfahan province). Based on their *CYP2D6* alleles, the patients were assigned to different genotype groups discriminating for CYP2D6 phenotypes by CYP2D6 activity scores (AS) ([@B12]). Plasma concentrations of tamoxifen and its metabolites following a standard tamoxifen dose of 20 mg/day were correlated with CYP2D6 phenotype. In patients with an activity score of one or less, the standard tamoxifen dose was adjusted accordingly to 40 mg. Follow-up after 4 and 8 months after dose adjustment was performed and plasma levels of tamoxifen and its metabolites as well as adverse events were assessed.

Materials and Methods {#s1}
=====================

Patients
--------

A total of 134 patients diagnosed with estrogen and/or progesterone receptor positive breast cancer, were enrolled in the Breast Cancer Research Center in Isfahan province, Iran. The main characteristics of the patients incorporated in the study, are presented in [Table 1](#T1){ref-type="table"}. Peripheral blood (5 ml) was collected from each patient in sterile tubes containing EDTA. A fixed time of blood collection was waived, since PBPK simulations showed only small fluctuations of endoxifen plasma levels within the dosing interval ([@B24]). The study was approved by the Ethical Committee of Isfahan University of Medical Sciences and written informed consent was obtained from all patients.

###### 

The main characteristics of the patients.

  Characteristics                    All patients enrolled Number of patients (%) *N* = 134 (100)   Patients receiving 20 mg/day Number of patients (%) *N* = 117 (100)   Patients receiving 30 or 40 mg/day Number of patients (%) *N* = 17 (100)
  ---------------------------------- -------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------------
  **Age (years)**                                                                                                                                                         
  Median                             45                                                             45                                                                    46
  Range                              28--71                                                         28--71                                                                34--68
  **BMI**                                                                                                                                                                 
  Median                             22                                                             22                                                                    23
  Range                              18--32                                                         18--32                                                                19.5--30
  **Menopausal status**                                                                                                                                                   
  Premenopausal                      60 (44.8)                                                      57 (48.7)                                                             3 (17.7)
  Postmenopausal                     70 (52.2)                                                      56 (47.9)                                                             14 (82.3)
  Unknown                            4 (3.0)                                                        4 (3.4)                                                               0 (0.0)
  **Chemotherapy**                                                                                                                                                        
  Yes                                116 (86.6)                                                     100 (85.5)                                                            16 (94.1)
  No                                 15 (11.2)                                                      14 (12.0)                                                             1 (5.9)
  Unknown                            3 (2.2)                                                        3 (2.5)                                                               0 (0.0)
  **Radiation**                                                                                                                                                           
  Yes                                122 (91.1)                                                     105 (89.7)                                                            17 (100)
  No                                 9 (6.7)                                                        9 (7.7)                                                               0 (0.0)
  Unknown                            3 (2.2)                                                        3 (2.6)                                                               0 (0.0)
  **Duration of tamoxifen use**                                                                                                                                           
  \>4 months, ≤2 years               81 (60.4)                                                      71 (60.7)                                                             10 (58.8)
  \>2 years                          53 (39.6)                                                      46 (39.3)                                                             7 (41.2)
  **Tumor size (cm)**                                                                                                                                                     
  ≤2                                 33 (24.6)                                                      31 (26.5)                                                             2 (11.8)
  2.1--5                             67 (50.0)                                                      57 (48.7)                                                             10 (58.8)
  \>5                                11 (8.2)                                                       9 (7.7)                                                               2 (11.8)
  Unknown                            23 (17.2)                                                      20 (17.1)                                                             3 (17.6)
  **Grading**                                                                                                                                                             
  G1                                 16 (11.9)                                                      15 (12.8)                                                             1 (5.9)
  G2                                 62 (46.3)                                                      54 (46.2)                                                             8 (47.1)
  G3                                 32 (23.9)                                                      31 (26.5)                                                             1 (5.9)
  Unknown                            24 (17.9)                                                      17 (14.5)                                                             7 (41.2)
  **Nodal status**                                                                                                                                                        
  Negative                           51 (38.0)                                                      42 (35.9)                                                             9 (52.9)
  Positive                           62 (46.3)                                                      56 (47.9)                                                             6 (35.3)
  Unknown                            21 (15.7)                                                      19 (16.2)                                                             2 (11.8)
  **Estrogen receptor status**                                                                                                                                            
  Positive                           127 (94.8)                                                     111 (94.9)                                                            16 (94.1)
  Negative                           2 (1.5)                                                        2 (1.7)                                                               0 (0.0)
  Unknown                            5 (3.7)                                                        4 (3.4)                                                               1 (5.9)
  **Progesterone receptor status**                                                                                                                                        
  Positive                           121 (90.3)                                                     105 (89.8)                                                            16 (94.1)
  Negative                           6 (4.5)                                                        6 (5.1)                                                               0 (0.0)
  Unknown                            7 (5.2)                                                        6 (5.1)                                                               1 (5.9)
  **HER-2 status**                                                                                                                                                        
  Positive                           16 (11.9)                                                      14 (12.0)                                                             2 (11.8)
  Negative                           106 (79.1)                                                     94 (80.3)                                                             12 (70.6)
  Unknown                            12 (9.0)                                                       9 (7.7)                                                               3 (17.6)

BMI, Body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Genotyping
----------

Genomic DNA was extracted from 200 μl of a peripheral blood sample of each patient using QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). All patients included in this study were genotyped for *CYP2D6*^∗^2, ^∗^4, ^∗^6, ^∗^10, ^∗^17, and ^∗^41 alleles by TaqMan^®^ allelic discrimination assays (Applied Biosystems, Foster City, CA, United States) according to the manufacturer's instructions. Determination of *CYP2D6* gene deletion (*CYP2D6^∗^5*) and duplication was performed using a pre-developed TaqMan^®^ *CYP2D6* Copy Number Assay (Hs00010001_cn, Thermo Fisher Scientific) and as a reference the TaqMan^®^ Copy Number Reference Assay RNase P (Thermo Fisher Scientific) as previously described (Schroth; Front Pharmacol 2017). Real-time PCR analyses were carried out according to the manufacturer's instructions on a 7900 Real-Time PCR System (Thermo Fisher Scientific) and data were analyzed with the SDS2.4 software. In the present study, alleles are assigned according to the nomenclature for human *CYP2D6* alleles as previously published ([@B40]). Samples with one loss of function or reduced activity allele and a copy number of 3 were assigned EM phenotype. The allele frequencies were tested for deviation from the Hardy Weinberg equilibrium using the exact test^[1](#fn01){ref-type="fn"}^.

Clinical Trial Design and Endpoints
-----------------------------------

Pre- and postmenopausal breast cancer patients (*n* = 134) who were on standard tamoxifen therapy of 20 mg daily for at least 4 months with normal liver and kidney function were enrolled. Exclusion criteria as defined by the SmPC were pregnancy and breastfeeding and co-medication with a known CYP2D6 inhibitor. In addition, patients with a tamoxifen plasma concentration \<100 nM at study baseline were excluded because this low plasma concentrations implied that these patients had missed at least one daily dose prior to sampling ([Figure 2](#F2){ref-type="fig"}). The study design was as follows: Patients with EM/EM or EM/IM genotypes (activity score \> 1) continued tamoxifen therapy at the standard dosage of 20 mg/day. Patients with EM/PM or IM/IM genotypes (activity score 1) received 30 mg/day (given as once 10 mg and once 20 mg) and patients with IM/PM or PM/PM genotypes (activity score 0.5 and 0, respectively) received 40 mg/day (given as 20 mg twice). Registration ID in IRCT was: IRCT2015082323734N1^[2](#fn02){ref-type="fn"}^.

![Flow chart of patients' enrollment and sampling during the clinical trial.](fphar-10-00530-g002){#F2}

During the follow-up period of 8 months plasma samples for the analysis of tamoxifen and its metabolites were drawn 4 and 8 months after inclusion of the patients. After 8 months the study was terminated. The decision whether treatment of patients with dose adjustment for tamoxifen should be continued was completely under the responsibility of the attending physician.

Measuring the Concentration of Tamoxifen and Its Metabolites in Plasma
----------------------------------------------------------------------

The plasma concentrations of tamoxifen and its metabolites were analyzed before and after 4 and 8 months of dose adjustment using LC-MS/MS as previously described ([@B33]).

In brief, sample preparation was carried out by protein precipitation and dilution. For calibration and method validation, calibration samples and quality controls were prepared by adding mixtures of all reference compounds in acetonitrile to blank plasma. Final concentrations of calibration samples were chosen according to the concentrations of metabolites expected in plasma of patients under steady state condition (for calibration ranges see [Supplementary Table S1](#SM1){ref-type="supplementary-material"}). For α-OH-DM-Tam no pure reference material was available; plasma concentrations were calculated using the calibration data of α-OH-Tam.

Chromatographic separation of tamoxifen and its metabolites was performed using a ZORBAX Eclipse plus C18 (Agilent Technologies, Waldbronn, Germany) and 1200 rapid resolution LC-system (Agilent) with a binary pump using a gradient of 0.1% formic acid in acetonitrile in 0.1% formic acid in water. A 6460 triple quadrupole mass spectrometer (Agilent) equipped with a Jet Stream electrospray source (Agilent) was used for MRM. MRM transitions, retention times and internal standards are given in the [Supplementary Table S1](#SM1){ref-type="supplementary-material"}.

Toxicities Evaluation
---------------------

Adverse events before and during the study were evaluated by questionnaire according to CTCAE v4.0. In addition, standard laboratory parameters such as ALT, AST, ALP, BUN, and creatinine were determined before and after 4 and 8 months.

Statistical Analysis
--------------------

For statistical analysis, SPSS software version 16.0 (SPSS, Inc., Chicago, IL, United States) was utilized. The differences of the plasma concentrations of tamoxifen and its metabolites between different genotypes were evaluated using Kruskal--Wallis test followed by Dunn's *post hoc* test. The concentrations of tamoxifen and its metabolites before and after tamoxifen dose escalation were compared using Friedman's test followed by Dunn's multiple comparison test as a *post hoc* which compared 0 with 4, 0 with 8, and 4 with 8 months. The Friedman's test was also applied to evaluate the associations between the increase of tamoxifen dosage and the incidence of adverse events. The results were considered statistically significant if the *p* value was less than or equal to 0.05.

Results
=======

Allele and Genotype Frequencies and Assigned CYP2D6 Phenotypes
--------------------------------------------------------------

*CYP2D6* ^∗^1, ^∗^2, ^∗^4, ^∗^5, ^∗^6, ^∗^10, ^∗^17, and ^∗^41 alleles were successfully genotyped in 134 breast cancer patients. For copy number analysis 2 samples showed ambiguous results and therefore were excluded from further analysis ([Figure 2](#F2){ref-type="fig"}). Allele and genotype frequencies of the study population are given in [Supplementary Table S2](#SM1){ref-type="supplementary-material"}. All genotypes were in Hardy--Weinberg equilibrium (*p* \> 0.05).

Genotypes and the respective phenotypes based on the CYP2D6 activity score (AS) are shown in [Table 2](#T2){ref-type="table"}. The following phenotypes were assigned: UM (AS 3): ^∗^1/^∗^1, ^∗^1/^∗^2 or ^∗^2/^∗^2 and a copy number ≥ 3; EM/EM (AS: 2): ^∗^1/^∗^1, ^∗^1/^∗^2, ^∗^2/^∗^2, and ^∗^1/^∗^41 and ^∗^1/^∗^4 with copy number = 3; EM/IM (AS: 1.5): ^∗^1/^∗^10, ^∗^1/^∗^17, ^∗^1/^∗^41, and ^∗^2/^∗^41; EM/PM (AS: 1): ^∗^1/^∗^4; IM/IM (AS: 1): ^∗^10/^∗^10, ^∗^10/^∗^41, and ^∗^41/^∗^41; IM/PM (AS 0.5): ^∗^41/^∗^5; PM/PM (AS: 0): ^∗^4/^∗^4 and ^∗^4/^∗^6.

###### 

*CYP2D6* phenotypes assigned according to the CYP2D6 activity scores and respective *CYP2D6* genotypes.

  CYP2D6 phenotype                  *CYP2D6*            
  ------------------ ---- --------- -------------- ---- ---------
  UM (3)             11   (8.33)    ^∗^1/^∗^1xN    2    (1.52)
                                    ^∗^1/^∗^2xN    6    (4.55)
                                    ^∗^2/^∗^2xN    3    (2.27)
  EM (2)             68   (51.51)   ^∗^1/^∗^1      16   (12.12)
                                    ^∗^1/^∗^2      23   (17.42)
                                    ^∗^2/^∗^2      26   (19.7)
                                    ^∗^1/^∗^41xN   2    (1.52)
                                    ^∗^1/^∗^4xN    1    (0.76)
  EM/IM (1.5)        21   (15.90)   ^∗^1/^∗^10     5    (3.79)
                                    ^∗^1/^∗^17     1    (0.76)
                                    ^∗^1/^∗^41     14   (10.61)
                                    ^∗^2/^∗^41     1    (0.76)
  EM/PM (1)          23   (17.42)   ^∗^1/^∗^4      19   (14.39)
                                    ^∗^1/^∗^5      3    (2.27)
                                    ^∗^2/^∗^5      1    (0.76)
  IM/IM (1)          4    (3.03)    ^∗^10/^∗^10    1    (0.76)
                                    ^∗^10/^∗^41    1    (0.76)
                                    ^∗^41/^∗^41    2    (1.52)
  IM/PM (0.5)        1    (0.76)    ^∗^41/^∗^5     1    (0.76)
  PM (0)             4    (3.03)    ^∗^4/^∗^4      2    (1.52)
                                    ^∗^4/^∗^5      1    (0.76)
                                    ^∗^4/^∗^6      1    (0.76)

Plasma Concentrations of Tamoxifen and Its Metabolites at Baseline
------------------------------------------------------------------

Steady-state plasma concentrations of tamoxifen and its metabolites before dose escalation were measured by LC-MS/MS ([Table 3](#T3){ref-type="table"}). The mean concentration of tamoxifen at baseline was 378 ± 176 nmol/l (*n* = 117). The most abundant metabolites of tamoxifen were N-desmethyl-tamoxifen (DM-Tam) whose concentration was approximately twice the concentration of tamoxifen followed by N,N-didesmethyltamoxifen (DDM-Tam), and (Z)-endoxifen. In contrast, the plasma concentrations of the other highly potent tamoxifen metabolite, (Z)-4-hydroxytamoxifen \[(Z)-4-OH-Tam\] was less than 1/5 of the concentration of (Z)-endoxifen. Of note, the less potent 3-hydroxylated metabolites 3-hydroxy-N-desmethyltamoxifen (3-OH-DM-Tam) and 3-hydroxytamoxifen (3-OH-Tam) showed only low concentrations compared to the respective 4-hydroxy-isomers. The concentrations of the (E)-isomers of both highly active metabolites, were highly variable and accounted for only 1/10 of that of (Z)-endoxifen and (Z)-4-OH-Tam, respectively. Interestingly, with respect to the glucuronides this difference in concentration was less pronounced (0.582 ± 0.377 nmol/l for (Z)-DM-Tam-4-O-Gluc vs. 1.9 ± 1.35 nmol/l for (E)-DM-Tam-4-O-Gluc) pointing to a more rapid glucuronidation of the (E)-isomer.

###### 

Steady state plasma concentrations of tamoxifen and its metabolites in breast cancer patients receiving 20 mg/day tamoxifen (*n* = 117^∗^).

  Compound                  Mean ± SD (nM)
  ------------------------- ----------------
  Tam                       378 ± 176
  Tam-NO                    21.7 ± 10.7
  DM-Tam                    675 ± 312
  DDM-Tam                   120.5 ± 52.9
  (Z)-Endoxifen             29.6 ± 17.1
  (E)-Endoxifen             4.92 ± 6.4
  (Z)-4'-OH-DM-Tam          15.1 ± 7.7
  (E)-4'-OH-DM-Tam          1.62 ± 1.28
  3-OH-DM-Tam               3.16 ± 2.14
  α-OH-DM-Tam^//^           3.38 ± 1.84
  (Z)-4-OH-Tam^\#^          5.3 ± 3.14
  (Z)-4'-OH-Tam^\#^         5.83 ± 2.99
  3-OH-Tam                  1.015 ± 0.647
  α-OH-Tam                  1.352 ± 0.721
  (Z)-OH-DDM-Tam^\#^        4.04 ± 2.29
  Tam-N-Gluc                0.919 ± 0.755
  (Z)-DM-Tam-4-O-Gluc^§^    0.582 ± 0.377
  (E)-DM-Tam-4-O-Gluc^\$^   1.9 ± 1.35
  (E)-Tam-4-O-Gluc^\$^      0.551 ± 0.405

∗

Non-adherent patients with plasma Tam concentrations \<100 nM were excluded.

//

No reference compound available. Quantification was done using the calibration curve of α-OH-Tam.

\#

The respective (E)-isomers could be quantified only in a minority of samples at low concentrations.

§

This glucuronide results from the conjugation of (E)-4-OH-DM-Tam.

\$

These glucuronides result from conjugation of (Z)-endoxifen and (Z)-4-OH-Tam, respectively.

Relationship Between *CYP2D6* Genotypes and Plasma Metabolite Concentrations
----------------------------------------------------------------------------

As CYP2D6 mediates a major step in the bioactivation of tamoxifen, we investigated the relationship between *CYP2D6* genotypes and the concentrations of tamoxifen and its metabolites ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table S3](#SM1){ref-type="supplementary-material"}). Using Kruskal--Wallis test, the mean concentrations of (Z)-endoxifen, (E)-endoxifen and their respective glucuronides, (Z)-4-OH-Tam, 3-OH-DM-Tam, and 3-OH-Tam were significantly different between genotype groups (*p* \< 0.05). Despite considerable inter-individual variability within the genotype groups, all these metabolites showed increasing plasma concentrations with increasing CYP2D6 activity. However, 4′-hydroxy-N-desmethyltamoxifen (4′-OH-DM-Tam) showed an inverse correlation with lower plasma concentrations in patients with higher CYP2D6 activity (*p* = 0.0022). On the other hand, there was no significant difference in plasma concentrations of tamoxifen, tamoxifen-N-oxide, DM-Tam, DDM-Tam, α-hydroxytamoxifen (a-OH-Tam) and α-hydroxy-N-desmethyltamoxifen (a-OH-DM-Tam). As (Z)-endoxifen can undergo chemical or enzymatic isomerization into (E)-endoxifen we also analyzed the sum of both isomers revealing an even better correlation with CYP2D6 activity (*p* \< 0.0001). As a surrogate parameter for the intrinsic enzyme activity the MR of (Z)-endoxifen to DM-Tam correlates very well with CYP2D6 activity (*p* \< 0.0001).

![Plasma concentrations of selected tamoxifen metabolites stratified according to *CYP2D6* genotype in 117 Iranian breast cancer patients receiving 20 mg/day tamoxifen for at least 4 months. Non-adherent patients with plasma tamoxifen concentrations \<100 nM were excluded. The patients who were scheduled for the dose escalation trial are depicted in red. The differences between the genotype groups were assessed by Kruskal--Wallis Test.](fphar-10-00530-g003){#F3}

Concentration of Tamoxifen and Its Metabolites Following Dose Adjustment
------------------------------------------------------------------------

Dose adjustment in patients with an activity score of 0--0.5 (*n* = 2) and 1 (*n* = 15) to 40 and 30 mg/day, respectively, resulted in a significant increase in median plasma concentrations of tamoxifen and all metabolites except the (E)-isomers of endoxifen and 4′-OH-DM-Tam and (E)-Tam-4-O-Gluc ([Supplementary Table S4](#SM1){ref-type="supplementary-material"}). After 8 months the median plasma concentrations increased by about 26--122% compared to baseline. Plasma concentrations of tamoxifen and its main metabolites and the MR (Z)-endoxifen/DM-Tam during dose escalation are shown in [Figure 4](#F4){ref-type="fig"}. Due to the unexplained high variability of isomerization the concentrations of the isomers of endoxifen were additionally evaluated in sum. Of note, the MR endoxifen/DM-Tam did not change upon dose escalation. In line with this data, the increased intake of tamoxifen did not change the MR of other reactions involved in the formation or clearance of the anti-estrogenic metabolites (Z)-4-OH-Tam and (Z)-endoxifen.

![Plasma concentrations of tamoxifen and its main metabolites and the MR (Z)-endoxifen/DM-Tam in patients (*n* = 17) before and after dose escalation. Patients genotyped for *CYP2D6* as intermediate metabolizer (*n* = 15) (EM/PM or IM/IM) received 30 mg/day of tamoxifen and patients genotyped as poor metabolizers (*n* = 2) (PM/PM, IM/PM) received 40 mg/day. Plasma samples were drawn 4 and 8 months after dose adjustment and tamoxifen and its metabolites were quantified by UHPLC-MS/MS. The two patients who received 40 mg tamoxifen are shown in red.](fphar-10-00530-g004){#F4}

Adherence to Therapy
--------------------

Among the 17 patients who completed the dose adjustment protocol compliance of study medication has been considered entirely satisfactory: 47.1% (*n* = 8) did not miss any tamoxifen dose, 29.4% (*n* = 5) and 17.6% (*n* = 3) missed 1--5 and 6--10 doses, respectively. One patient reported more than 10 missing tamoxifen doses.

Toxicities and Adverse Events
-----------------------------

No woman was withdrawn from the study due to metastasis, thromboembolic or other serious adverse events. Vomiting, nausea, sexual pain, bloating, and irritability were significantly more frequent in the patients under tamoxifen dose escalation ([Table 4](#T4){ref-type="table"}; Friedman test, *P* \< 0.05). No changes in ALT, AST, ALP, BUN, and creatinine levels have been observed upon dose escalation.

###### 

Side effects are shown in patients without dose escalation (*n* = 117) and for dose adjusted patients (*n* = 17) before, after 4 and 8 months of dose adjustment.

  Test Side effects      Tamoxifen dosage        Time point   Number of patients reporting   Friedman *p*-value             
  ---------------------- ----------------------- ------------ ------------------------------ -------------------- ---- ---- -------
  Hot flashes            20 mg/day (*n* = 117)                13                             34                   40   30   
                         Dose escalation         Baseline     2                              4                    6    5    0.439
                         group (*n* = 15)        4 months     3                              5                    5    4    
                                                 8 months     5                              2                    4    6    
  Cold sweat             20 mg/day (*n* = 117)                58                             20                   22   17   
                         Dose escalation         Baseline     9                              3                    3    2    0.358
                         group (*n* = 15)        4 months     8                              6                    1    2    
                                                 8 months     6                              4                    4    3    
  Night sweat            20 mg/day (*n* = 117)                44                             27                   25   21   
                         Dose escalation         Baseline     7                              4                    3    3    0.509
                         group (*n* = 15)        4 months     6                              8                    2    1    
                                                 8 months     6                              4                    4    3    
  Vaginal irritation     20 mg/day (*n* = 117)                72                             22                   21   2    
                         Dose escalation         Baseline     10                             3                    4    0    0.152
                         group (*n* = 15)        4 months     7                              3                    4    3    
                                                 8 months     6                              3                    2    6    
  Vaginal bleeding       20 mg/day (*n* = 117)                102                            3                    8    4    
                         Dose escalation         Baseline     15                             0                    1    1    0.662
                         group (*n* = 15)        4 months     13                             1                    3    0    
                                                 8 months     13                             1                    1    2    
  Vaginal dryness        20 mg/day (*n* = 117)                55                             44                   17   1    
                         Dose escalation         Baseline     7                              7                    3    0    0.549
                         group (*n* = 15)        4 months     7                              4                    4    2    
                                                 8 months     7                              3                    3    4    
  Sexual unwillingness   20 mg/day (*n* = 117)                44                             26                   26   21   
                         Dose escalation         Baseline     6                              3                    4    4    0.692
                         group (*n* = 15)        4 months     7                              3                    4    3    
                                                 8 months     6                              3                    5    3    
  Sexual pain            20 mg/day (*n* = 117)                58                             44                   9    6    
                         Dose escalation         Baseline     8                              8                    0    1    0.002
                         group (*n* = 15)        4 months     6                              5                    2    4    
                                                 8 months     6                              3                    4    4    
  Weight gain            20 mg/day (*n* = 117)                53                             34                   12   18   
                         Dose escalation         Baseline     8                              4                    2    3    0.309
                         group (*n* = 15)        4 months     6                              5                    2    4    
                                                 8 months     7                              4                    3    3    
  Dizziness              20 mg/day (*n* = 117)                54                             53                   4    6    
                         Dose escalation         Baseline     8                              8                    0    1    0.727
                         group (*n* = 15)        4 months     7                              7                    0    3    
                                                 8 months     8                              6                    0    3    
  Vomiting               20 mg/day (*n* = 117)                101                            12                   4    0    
                         Dose escalation         Baseline     15                             2                    0    0    0.009
                         group (*n* = 15)        4 months     12                             4                    1    0    
                                                 8 months     10                             6                    1    0    
  Diarrhea               20 mg/day (*n* = 117)                104                            13                   0    0    
                         Dose escalation         Baseline     15                             2                    0    0    0.819
                         group (*n* = 15)        4 months     14                             3                    0    0    
                                                 8 months     14                             2                    0    1    
  Bloating               20 mg/day (*n* = 117)                46                             34                   22   15   0.023
                         Dose escalation         Baseline     7                              4                    3    3    
                         group (*n* = 15)        4 months     4                              3                    6    4    
                                                 8 months     5                              4                    5    3    
  Mood swing             20 mg/day (*n* = 117)                14                             66                   26   11   
                         Dose escalation         Baseline     2                              9                    4    2    0.423
                         group (*n* = 15)        4 months     3                              4                    7    3    
                                                 8 months     4                              4                    6    3    
  Irritability           20 mg/day (*n* = 117)                24                             50                   31   12   
                         Dose escalation         Baseline     3                              7                    5    2    0.006
                         group (*n* = 15)        4 months     3                              2                    6    6    
                                                 8 months     4                              1                    7    5    

Discussion
==========

There is increasing evidence that personalized therapy in oncology contributes significantly to better treatment outcome with a tolerable safety ([@B32]; [@B36]). Recently, genotyping of *CYP2D6* in patients undergoing tamoxifen therapy for premenopausal and postmenopausal breast cancer patients has been proposed to improve treatment outcome ([@B35];[@B14]). Previous clinical trials in breast cancer showed first evidence that *CYP2D6* dose-adjusted treatment of tamoxifen resulted in significantly increased plasma concentrations of endoxifen, the major active metabolite of tamoxifen ([@B3]; [@B18]; [@B23]; [@B7]; [@B9]; [@B11]; [@B16]).

To the best of our knowledge currently no data are available demonstrating the feasibility of individualized *CYP2D6* guided tamoxifen therapy in an Iranian population of breast cancer patients. Therefore, we initiated a prospective clinical pilot study to adjust tamoxifen dosage in ER^+^ breast cancer patients with Iranian ethnic background. Considering major differences of *CYP2D6* allele frequencies world-wide ([@B48]), genotyping of *CYP2D6* was performed covering *CYP2D6* alleles relevant for the Middle East population ([@B41]; [@B2]). Based on our study protocol and in agreement with previous studies elucidating the impact of *CYP2D6*-guided tamoxifen dose adjustment in patients with compromised CYP2D6 activity (PM and IM), plasma concentrations of tamoxifen and selected metabolites were quantified before, after 4 and 8 months of dose escalation. In addition to DM-Tam, (Z)-endoxifen, and 4-OH-Tam which are suggested to be clinically relevant, we comprehensively measured other tamoxifen metabolites by a previously established and validated sensitive and highly specific LC-MS/MS method ([@B33]). This method includes various hydroxylated metabolites and glucuronides ([Figure 1](#F1){ref-type="fig"}; [@B5]).

At baseline, the inter-individual variability of tamoxifen and selected metabolites in the Iranian population was similar to data in other ethnic populations of breast cancer patients (e.g., Europe, America and Asians) ([@B37]). Regarding (Z)-endoxifen, our data confirms the close relationship between *CYP2D6* genotypes and plasma concentrations proposed by other studies ([@B27]; [@B1]; [@B39]; [@B46]). Due to the small number of patients who were enrolled in our pilot study to evaluate dose escalation of tamoxifen in Iranian breast cancer, data analyses have been performed by combining IM and PM patients treated with 30 and 40 mg tamoxifen per day, respectively. Generally our data demonstrate a significant increase in plasma concentrations of tamoxifen and its metabolites following dose escalation for 4 and 8 months. Of note, (Z)-endoxifen plasma concentrations in patients with compromised CYP2D6 activity and dose escalation were similar to those in patients with CYP2D6 EM phenotype at standard dosage.

These data are in line with previous studies demonstrating that dose escalation of tamoxifen in CYP2D6 compromised breast cancer patients result in higher plasma levels of the active metabolite endoxifen. In the study by [@B18] in a US American population the concentration of endoxifen was increased in both, the IM and PM patients, after doubling the tamoxifen dosage to 40 mg/day for 4 months. The endoxifen plasma levels in the IM group receiving 40 mg/day tamoxifen were similar to the EM group treated with 20 mg/day (21.8 vs. 29.2 ng/ml; *p* = 0.84). In contrast, patients in the PM group failed to reach similar endoxifen plasma levels (12.9 vs. 29.2 ng/ml; *p* = 0.016) despite dose escalation. [@B3] increased the tamoxifen dosage from 20 to 30 mg/day based on plasma endoxifen concentration (\<40 nmol/l) in US patients with various ethnic background and IM CYP2D6 phenotype. Dose adjustment resulted in elevated levels of (Z)-endoxifen, (Z)-4′-OH-DM-Tam, (Z)-4-OH-Tam, and (Z)-4′-OH-Tam. Noteworthy, in line with our data lower plasma concentrations of (Z)-4′-OH-DM-Tam in patients with an EM CYP2D6 activity score compared to IM/PM patients were reported, indicating a metabolic shift from (Z)-4′-OH-DM-Tam to endoxifen. In an Asian population [@B23] investigated dose escalation of tamoxifen to 30 and 40 mg/day in patients who were heterozygous and homozygous for *CYP2D6* IM alleles, respectively. After 8 weeks, concentrations of tamoxifen, N-DM-Tam, 4-OH-Tam and endoxifen were increased in IM patients resulting in endoxifen and 4-OH-Tam levels similar to those detected in EM patients. After enrollment of the patients in the CYPTAM study, tamoxifen dose escalation for IM and PM patients was calculated by the formula: 20 mg × (average endoxifen serum concentration in EMs divided by the patient's baseline endoxifen serum concentration) and led to tamoxifen doses between 30--100 mg for the IMs and 60--120 mg for PMs ([@B9]). Dose adjustment resulted in elevated levels of endoxifen in both PMs and IMs. There was no significant difference with the mean endoxifen level in EMs (=33.7 nM), and IMs after dose escalation (=30.3 nM; *p* = 0.20), although the mean endoxifen level in PMs after dose escalation was significantly lower (=27.3 nM; *p* = 0.03).

Building on the success of the pilot study by [@B18] and [@B16] expanded enrollment to 500 patients and again they doubled the tamoxifen dosage from 20 to 40 mg/day in both, the IM and PM patients. After 4 months, the endoxifen plasma levels in the genotype-dosed IM patients, had risen by 48% to 10.74 ng/mL, which was no longer different from, and was in fact nominally greater than, the endoxifen concentrations in EM/UM patients (9.30 ng/mL, *p* = 0.08). Endoxifen concentrations in genotype-dosed PM patients also rose by approximately 61% to 5.52 ng/mL but remained significantly lower than in EM/ UM patients (9.30 ng/ml; *p* = 0.009). In the Australian TADE study patients with basal endoxifen concentrations \<30 nmol/l underwent a sequential dose escalation scheme with a maximum tamoxifen dose of 60 mg/day resulting in endoxifen concentrations \>30 nmol/l in 76% (93 of 122) of participants ([@B11]). Of note patients with a PM phenotype, i.e., carrying two non-functional *CYP2D6* alleles were unable to achieve the target endoxifen concentration of 30 nmol/l despite dose escalation.

Independent from *CYP2D6* genotype increased dosing of tamoxifen to 30 and 40 mg/day resulted in significantly higher plasma levels of tamoxifen compared to tamoxifen standard treatment (20 mg/day).

Since altered pharmacokinetics may result in a higher rate of ADR, we systematically monitored tamoxifen specific side effects as well as laboratory parameters indicating liver and kidney toxicity. No severe side effects (e.g., thromboembolism) occurred during dose escalation. Moreover there was no significant increase in the occurrence of hot flashes and only slightly increased frequencies of vomiting and agitation. These data corroborate previous studies demonstrating that doses escalation of tamoxifen in CYP2D6 compromised breast cancer patients is well tolerated ([@B3]; [@B18]; [@B23]; [@B9]; [@B11]; [@B16]).

Besides CYP2D6, CYP2C9, and CYP2C19 as well as some phase 2 enzymes have also been reported to participate in tamoxifen pharmacokinetics, however, with far less impact than CYP2D6 ([@B33]; [@B37]; [@B30]; [@B43]). Therefore, this study was focused on CYP2D6.

A limitation of our study is the number of patients included. Previous studies have shown a low frequency of CYP2D6 PM subjects in the Iranian population ([@B25]; [@B15]; [@B2]). In line with these findings, the number of PM patients was not high enough to analyze those patients separately. Moreover no outcome data are available.

Taken together, for the first time we showed that the concept of dose escalation of tamoxifen in CYP2D6 compromised breast cancer patients is feasible in an Iranian population resulting in significantly higher plasma concentrations of the active metabolite (Z)-endoxifen. Our study supports ongoing and future activities to comprehensively elucidate the impact of *CYP2D6*- guided dose escalation on clinical outcome in prospective clinical trials. The strategy of dose escalation in patients with compromised genetics for drug metabolizing enzymes regarding other drugs as tamoxifen appears to be a promising approach which warrants future trials.
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ADR

:   adverse drug reaction

ALP

:   alkaline phosphatase

ALT

:   Alanine transaminase

AST

:   Aspartate transaminase

BUN

:   blood urea nitrogen

CTCAE v4.0

:   Common Toxicity Criteria for Adverse Events, version 4

CYP2D6

:   cytochrome P450 2D6

DDM

:   N, N-DiDesmethyl

DM

:   N-desmethyl

EM

:   extensive metabolizer

ER

:   estrogen receptor

Gluc

:   Glucuronides

IM

:   intermediate metabolizer

IRCT

:   Iranian Registry of Clinical Trials

LC-MS/MS

:   liquid chromatography tandem mass spectrometry

MR

:   metabolic ratio

MRM

:   multiple reaction monitoring

OH

:   hydroxyl

PM

:   poor metabolizer

SPSS

:   Statistical Package for Social Sciences

Tam

:   tamoxifen

UM

:   ultra-rapid metabolizer
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